Table 3.
Clinical and hemodynamic data of all patients and subgroups
| Variables | VTE (n=7) | APS (n=6) | SCD (n=6) | P |
|---|---|---|---|---|
| Age (years) | 51.5 (±16.4) | 38.1 (±6.6) | 39.3 (±12.1) | 0.13 |
| Gender, n (%) | ||||
| Female | 4 (57) | 5 (83) | 5 (83) | 0.4 |
| Male | 3 (43) | 1 (17) | 1 (17) | |
| BMI | 32.6 (±6.7) | 34.5 (±8.1) | 25.6 (±6.4) | 0.1 |
| Symptoms duration (months) | 21.7 (±13.2) | 9.5 (±4) | 13 (±5.8) | 0.06 |
| WHO FC IV, n (%) | 3 (43) | 5 (83) | 2 (33) | |
| 6MWD (m) | 351 (±63.2) | 347 (±174) | 375 | 0.9 |
| NT-proBNP (pg/mL) | 420 (108-695) | 2657 (1502-19835) | 162 (13-10000) | 0.2 |
| TAPSE (mm) | 16.9 (±3.6) | 18.8 (±5.9) | 20.6 (±1.74) | 0.4 |
| RAP (mmHg) | 10.5 (±3.9) | 5.5 (±3) | 8.4 (±2.4) | 0.08 |
| mPAP (mmHg) | 44.5 (±13.3) | 39.7 (±15.7) | 36.6 (±5.7) | 0.5 |
| PCWP (mmHg) | 13 (±3.2) | 9.2 (±2.5) | 12.3 (±4.6) | 0.2 |
| PVR (WU) | 11.2 (±9.4) | 10.8 (±10) | 4.8 (±1.5) | 0.2 |
| CO (L/min) | 4.7 (±1.8) | 4 (±1.5) | 5.3 (±1.1) | 0.3 |
| CI (L/min/m2) | 2.4 (±0.7) | 2.3 (±0.8) | 3.2 (±0.5) | 0.07 |
WHO=World Health Organization, FC=Functional class, BMI=Body mass index, 6MWD=Six-min walk distance, RAP=Right atrial pressure, PVR=Pulmonary vascular resistance, mPAP=Mean pulmonary arterial pressure, PVR=Pulmonary vascular resistance, CO=Cardiac output, CI=Cardiac index, VTE=Venous thromboembolism, APS=Antiphospholipid syndrome, SCD=Sickle cell disease